Skip to content

Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma <= 2cm with Micropapillary and Solid Subtype Negative by Intraoperative Frozen Sections: a Prospective and Multi-Center Randomized Controlled Trial Study

Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma <= 2cm with Micropapillary and Solid Subtype Negative by Intraoperative Frozen Sections: a Prospective and Multi-Center Randomized Controlled Trial Study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017322
Enrollment
Unknown
Registered
2018-07-24
Start date
2019-08-20
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early-stage lung adenocarcinoma

Interventions

Sponsors

Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Patient aged 20–79 years old, both male or female; 2. Tumor size = 0.25); 5. Intraoperative frozen section confirmed invasive lung adenocarcinoma with micropapillary and solid subtype negative ( 1.5L or FEV1% >= 70%); 8. Eastern Cooperative Oncology Group, 0 to 2; 9. Volunteer to participate the trial and sign the informed consent, able to comply with the follow-up plan and other program requirements.

Exclusion criteria

Exclusion criteria: 1. Radiological pure ground glass nodules (consolidation to tumor ratio 5%); 4. Intraoperative frozen section confirmed adenocarcinoma in situ andminimally invasive adenocarcinoma; 5. Preoperative imaging examination or EBUS indicated lymph node positive metastasis; 6. preoperative imaging examination revealed distant metastasis; 7. Patients with severe damage to heart, liver and kidney function (grade 3 ~ 4, ALT and/or AST over 3 times the normal upper limit, Cr over the normal upper limit); 8. Patients with other malignant tumors; 9. Pregnant, planned pregnancy and lactating female patients (urine HCG>2500IU/L is diagnosed as early pregnancy); 10. Non prior chemotherapy, radiation therapy or any other therapies were performed; 12 participated in other tumors within three months of relevant clinical subjects; 11. Those who have participated in other tumor-related clinical trials within three months; 12. Those are not suitable for participating in trials according to investigator's assessment.

Design outcomes

Primary

MeasureTime frame
recurrence-free survival rate;

Secondary

MeasureTime frame
overall survival rate;Reduced pulmonary function after surgery;Incidence rate of perioperative mortality and complication;

Countries

China

Contacts

Public ContactChang Chen

Shanghai Pulmonary Hospital

chenthoracic@163.com+86 13917810850

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026